Resmed
ResMed Inc., a leading player in the sleep and respiratory care industry, is headquartered in the United States, with significant operations across Europe, Asia, and Australia. Founded in 1989, ResMed has consistently innovated in the development of cloud-connected devices and software solutions that enhance patient care and improve quality of life for those with sleep apnoea and chronic obstructive pulmonary disease (COPD). The company’s core offerings include advanced continuous positive airway pressure (CPAP) devices, portable oxygen concentrators, and digital health solutions, all designed to provide seamless integration and user-friendly experiences. ResMed's commitment to research and development has positioned it as a market leader, recognised for its pioneering technologies and significant contributions to the field of sleep medicine. With a strong focus on improving patient outcomes, ResMed continues to set benchmarks in the healthcare industry.
DitchCarbon Score
How does Resmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Resmed's score of 63 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Resmed's reported carbon emissions
In 2024, ResMed reported total carbon emissions of approximately 25,059,000 kg CO2e, with Scope 1 emissions at about 3,743,000 kg CO2e and Scope 2 emissions at approximately 21,317,000 kg CO2e. This represents a decrease from 2023, where total emissions were about 28,391,000 kg CO2e, with Scope 1 at approximately 4,453,000 kg CO2e and Scope 2 at around 23,939,000 kg CO2e. ResMed has set ambitious climate commitments, aiming for a 42% reduction in absolute Scope 1 and 2 greenhouse gas emissions by FY2030 from a FY2022 baseline. Long-term goals include a 90% reduction in these emissions by FY2050. Additionally, the company is committed to achieving net-zero emissions across its value chain by FY2050, with a specific target to reduce Scope 3 emissions by 51.6% per megawatt constructed within the same timeframe. To support these targets, ResMed plans to develop site emissions profiles and explore electrification opportunities for both Scope 1 and Scope 2 energy sources by 2025. These initiatives reflect ResMed's commitment to sustainability and its proactive approach to addressing climate change within the healthcare equipment sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Resmed is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
